폰빌레브란트병(VWD) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2026-2036년)

Von Willebrand Disease Market Outlook and Forecast

Thelansis's "Von Willebrand Disease (VWD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Von Willebrand Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Von Willebrand Disease (VWD) Overview

Von Willebrand disease is an inherited bleeding disorder caused by quantitative deficiency or qualitative dysfunction of von Willebrand factor, impairing platelet adhesion and, in some patients, factor VIII stability. Clinical severity varies widely, ranging from mild mucosal bleeding to severe recurrent hemorrhage. Current treatment includes desmopressin in responsive patients, VWF-containing concentrates, antifibrinolytic therapy, and prophylaxis for selected patients with severe or frequent bleeding. The therapeutic landscape has already advanced beyond episodic plasma-derived replacement: recombinant VWF vonicog alfa is FDA-approved for routine prophylaxis in adults with all VWD types, following a 2025 indication expansion, while Wilate received a further FDA expansion in 2026 to include routine prophylaxis in children younger than 6 years. These advances are shifting development toward reducing treatment frequency and infusion burden while maintaining sustained hemostatic protection. Emerging approaches include agents that prolong VWF exposure, such as HMB-002, targeted therapies such as rondoraptivon pegol for selected type 2B disease, and hemostatic rebalancing strategies such as VGA039. These approaches remain investigational, but they broaden the field beyond direct VWF replacement. For stakeholders, VWD represents a high-value rare-hematology opportunity where the next advances are likely to combine longer duration, less burdensome administration, and mechanism-specific hemostatic control.

Key Highlights

• In Spain, diagnosed VWD cases are projected to increase from 708 in 2026 to 789 by 2036.
• Von Willebrand Disease (VWD) is a common inherited bleeding disorder caused by deficient or defective von Willebrand factor.
• Bleeding episodes and disease severity vary widely across patients.
• Significant unmet need remains for therapies providing effective and sustained bleeding control.

Market Overview

• The Spain VWD market is projected to grow from $55M in 2026 to $95M by 2036.
• Market growth is driven by:
• Increasing adoption of factor replacement and targeted therapies
• Improved diagnosis and disease management
• Future growth will depend on therapies offering durable bleeding prevention and improved patient outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Hoffmann-La Roche
• Vega Therapeutics, Inc.
• Octapharma
• Takeda
• Hemab ApS
• Shanghai RAAS Blood Products Co., Ltd.
• Bioverativ, a Sanofi company
• Alnylam Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)